Japanese journal of ophthalmology · 2003
Influence of dorzolamide on corneal endothelium.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Inoue Kenji, Okugawa Kazuko, Oshika Tetsuro, Amano Shiro
Аннотация
PURPOSE: To evaluate the influence of topical 1% dorzolamide treatment for 3 months on the endothelial morphology and the thickness of the cornea.
METHODS: The corneal endothelium was investigated in 21 glaucoma patients (29 eyes) who received topical 1% dorzolamide treatment for 3 months. Intraocular pressure, corneal endothelium, and central corneal thickness (CCT) were measured before and 3 months after topical dorzolamide treatment. The relation between the endothelial cell density loss or the CCT increase, and factors such as the history of previous intraocular surgery, the presence of type II diabetes mellitus, type of glaucoma, intraocular pressure before treatment (above or below 20 mm Hg), or the kinds of eye drops used before dorzolamide treatment were evaluated.
RESULTS: The endothelial cell density, coefficient of variation of cell area, and percentage of hexagonal cells did not change significantly. The CCT after treatment (537 +/- 34 microm) was significantly increased over that before treatment (530 +/- 33 microm). There was no significant relation of endothelial cell loss or CCT increase to any of the above factors.
CONCLUSIONS: Topical 1% dorzolamide treatment increases CCT and does not affect corneal endothelial morphology.
METHODS: The corneal endothelium was investigated in 21 glaucoma patients (29 eyes) who received topical 1% dorzolamide treatment for 3 months. Intraocular pressure, corneal endothelium, and central corneal thickness (CCT) were measured before and 3 months after topical dorzolamide treatment. The relation between the endothelial cell density loss or the CCT increase, and factors such as the history of previous intraocular surgery, the presence of type II diabetes mellitus, type of glaucoma, intraocular pressure before treatment (above or below 20 mm Hg), or the kinds of eye drops used before dorzolamide treatment were evaluated.
RESULTS: The endothelial cell density, coefficient of variation of cell area, and percentage of hexagonal cells did not change significantly. The CCT after treatment (537 +/- 34 microm) was significantly increased over that before treatment (530 +/- 33 microm). There was no significant relation of endothelial cell loss or CCT increase to any of the above factors.
CONCLUSIONS: Topical 1% dorzolamide treatment increases CCT and does not affect corneal endothelial morphology.